Ann Arbor Pharmacometrics Group, a pharmacometrics consulting firm based in Ann Arbor, has been acquired by Amador Bioscience, a Pleasaton, Calif.-based global translational sciences and clinical pharmacology contract research organization. Financial terms of the acquisition were not disclosed.
Pharmacometrics is a field in which drug, disease, and trial information is quantified to aid development and regulatory decisions. A2PG’s specialties include data management, population pharmacokinetic and exposure-response modeling, pediatric modeling and simulation, clinical trial simulation, and strategic consulting.
“Bringing the teams together will allow us to offer a far more robust array of client services, all under one roof, and across the globe,” says Dr. Bing Wang, CEO and chairman of the board at Amador.
Wang says A2PG has successfully supported more than 200 biologic license application and new drug application submissions in the U.S. and overseas.
Wang says combined with A2PG, Amador Bioscience will become a one-stop global translational science and clinical pharmacology CRO supporting nonclinical, early- and late-stage clinical development.
“Working with Amador is going to help us stay at the forefront of biopharmaceutical development and pharmaceutical sciences,” says Sunny Chapel, founder and CEO of A2PG. “A2PG excels at the parts of the process that we handle, and Amador is likewise excellent at its specialties. With the companies merged, we’ll now have specialized experts to cover every step of the clinical pharmacology process.”
The company’s services encompass advanced modeling and simulation, statistical programming, noncompartmental analysis, laboratory services, translational medicine, early clinical development, and clinical pharmacology trials.